Regulus Therapeutics has appointed Aimee Jackson as its director of drug discovery.
Jackson previously served as a senior research fellow at Rosetta Inpharmatics, a unit of Merck. Earlier this year, Regulus announced that it had hired Peter Linsley, who had previously held various positions at Rosetta and Merck, as its CSO.
Jackson holds a PhD from the University of Colorado Health Science Center.
RXi Pharmaceuticals has named Anastasia Khvorova as its CSO.
Khvorova most recently served as CSO and vice president of research and development of Dharmacon, now a division of Thermo Fisher Scientific. Before joining Dharmacon, she was a research scientist at Amgen.
The Wisconsin Biotechnology & Medical Device Association has named Dave Rozema, a senior scientist at Roche subsidiary Mirus Bio, a winner of this year’s annual Rising Stars award.
According to WBMA, the awards recognize the biotech and medical device industries’ “next generation of leaders” based on their efforts at their particular company.
Rozema led the chemistry team that developed Mirus’ dynamic polyconjugate siRNA delivery technology, which was a major driver of Roche’s decision to acquire the company, WBMA said.